Analyst Price Target is $14.00
▲ +315.43% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Galectin Therapeutics in the last 3 months. The average price target is $14.00, with a high forecast of $14.00 and a low forecast of $14.00. The average price target represents a 315.43% upside from the last price of $3.37.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Galectin Therapeutics. This Buy consensus rating has held steady for over two years.
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.